A tattoo can be more than just a fashion statement – it has potential medical value, according to an article published in the online open access journal, Genetic Vaccines and Therapy.
Martin Müller and his team at the Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany, have shown that tattooing is a more effective way of delivering DNA vaccines than intramuscular injection. Using a coat protein from the human papillomavirus (HPV, the cause of cervical cancer) as a model DNA vaccine antigen, they compared delivery by tattooing the skin of mice with standard intramuscular injection with, and without, the molecular adjuvants that are often given to boost immune response.
The tattoo method gave a stronger humoral (antibody) response and cellular response than intramuscular injection, even when adjuvants were included in the latter. Three doses of DNA vaccine given by tattooing produced at least 16 times higher antibody levels than three intramuscular injections with adjuvant. The adjuvants enhanced the effect of intramuscular injection, but not of tattooing.
Tattooing is an invasive procedure done with a solid vibrating needle, causing a wound and sufficient inflammation to ‘prime’ the immune system. It also covers a bigger area of the skin than an injection, so the DNA vaccine can enter more cells. These effects may account for the stronger immune response arising from introducing a DNA vaccine into the body by tattooing. Of course, the tattooing approach may not be to everyone’s taste – as it is likely to hurt – but the researchers believe that it could have a role in, for instance, routine vaccination of cattle or in delivering therapeutic (rather than prophylactic) vaccines to humans.
‘Vaccination with naked DNA has been hampered by its low efficiency’ says Müller. ‘Delivery of DNA via tattooing could be a way for a more widespread commercial application of DNA vaccines’
Notes to Editors:
1. DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants
Dana Pokorna, Ivonne Rubio and Martin Müller
Genetic Vaccines and Therapy (in press)
During embargo, article available here: http://www.gvt-journal.com/imedia/1529292697163524_article.pdf?random=143500
After the embargo, article available at journal website: http://www.gvt-journal.com/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central’s open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication
2. Genetic Vaccines and Therapy is an Open Access, peer-reviewed, online journal dedicated to applying new knowledge about genetics in treating human disease
Genetic Vaccines and Therapy is aimed at researchers, clinicians and biotechnologists, worldwide, in the field of gene-based therapy and drug delivery. Examples of current topics of interest include: development of new biocompatible delivery materials, design of effective and safe vectors, exploration of new strategies for targeting drugs, and application of siRNA gene silencing to specific disease therapies. The field of genetic therapy is just beginning to see an increase in interest and applicability in the pharmaceutical and biotechnology community, and we have positioned this journal to meet the needs of workers in this new and highly promising area.
3. BioMed Central is an independent online publishing house committed to providing immediate access without charge to the peer-reviewed biological and medical research it publishes. This commitment is based on the view that open access to research is essential to the rapid and efficient communication of science.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.